Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California. The company trades on NMS exchange. The company headquarter is located in Carlsbad ,United States.

TickerDSGN
Long NameDesign Therapeutics, Inc.
Short NameDesign Therapeutics, Inc.